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Abstract
Active smoking is a recognized risk factor of various
infectious diseases. In a systematic review published
in BMC Public Health, Murray et al. demonstrated that
exposure to passive smoking significantly increased
the risk of meningococcal disease among children.
Their review especially highlights that the risk remains
high even if the exposure occurs during pregnancy or
after birth, although the authors could not
disentangle the independent effects of smoking
during pregnancy from those in the postnatal period.
How passive smoking increases the risk of childhood
meningococcal disease is not precisely known. Both
exposure to ‘smoke’, or ‘smokers’ (who are highly
susceptible to pharyngeal carriage of meningococci)
are postulated mechanisms, but unfortunately very
few studies have examined the risk of exposure by
considering these two variables separately, and this
therefore remains a research priority. Quitting may
well be the mainstay of preventing tobacco-related
hazards but the available global data suggest that
most smokers are reluctant to quit. Among other
interventions, immunizing children with a
meningococcal conjugate vaccine could, theoretically,
reduce the risk of meningococcal disease among
children and their smoker household contacts
through herd immunity.
See related article http://www.biomedcentral.com/
1471-2458/12/1062
Keywords: Conjugate meningococcal vaccine, inva-
sive meningococcal disease, meningococcal carriage,
passive smoking, quitting ratio
Commentary
A World Health Organization estimate suggests that
tobacco kills about 6 million people worldwide annually
with one tenth of these being non-smokers exposed to
second-hand smoke [1]. The effect of cigarette smoke
on various organs and systems of the body, ultimately
potentiating the risk of infection, is also well-recognized.
Exposure to tobacco smoke reduces neutrophil phagocy-
tic ability, depresses cytotoxic effects of natural killer
cells, decreases secretory immunoglobulin A, induces
oxidative stress and adversely affects immune responses,
including host response to vaccination [2].
The passive coating of buccal epithelial cells with com-
ponents of cigarette smoke can enhance binding of
potentially pathogenic bacteria, including meningococci.
A systematic review by Murray et al. published in BMC
Public Health has shown that household passive smoking
significantly increased the risk of meningococcal disease
in children [3]. This is consistent with at least one other
systematic review published recently that demonstrated
that not only the risk of meningococcal disease but also
the incidence of carriage was increased in children who
were exposed to second-hand smoking [4]. However,
Murray and colleagues noted that exposure of unborn or
newborn children to maternal smoking also increased the
risk of meningococcal disease in infants [3].
But how does the risk of meningococcal disease
increase in children exposed to passive smoking? One
line of reasoning is that the increased risks of meningo-
coccal disease and carriage are due to the effect of
exhaled smoke. This view is supported by observations
that environmental exposure to other smokes (for exam-
ple, kitchen smoke) can increase the risk of meningococ-
cal disease. A case-control study to investigate possible
risk factors among survivors of a meningitis epidemic in
1997 in northern Ghana demonstrated that cooking in
kitchens with firewood stoves increased the risk of
meningococcal meningitis nine-fold [5].
There is also evidence that contact with smokers, irre-
spective of whether they smoke within the household
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milieu, can increase risk. For instance, in a case-control
study examining whether there were medical and/or
environmental factors associated with meningococcal
carriage, Stuart and colleagues demonstrated that active
smoking and the presence of other smokers were inde-
pendently associated with meningococcal carriage [6].
The authors explained that the higher risk of carriage in
those who live with smokers may be due to the greater
chance of acquiring meningococci from contact with
smokers and ‘not to a direct effect of passive smoking.’
This notion is also supported in respect of meningococ-
cal disease by prospective population-based case-control
studies conducted in Australia and the UK [7-9]. An
Australian study showed that having a smoker amongst
close contacts increased the odds of having meningococ-
cal disease by 3.7 times [7], while one UK study showed
that the odds ratios increased with the number of smo-
kers in the household [8], and another UK study indi-
cated that the principal risk attributable to passive
smoking was in fact due to exposure to the smoker
rather than the smoke [9].
Additionally, there is evidence that smoking outside the
home only, as reported by parents, does not reduce nico-
tine levels in the hair of children, possibly indicating that
smokers continue to exhale nicotine after the actual time
of smoking [10]. These studies suggest that the risk of
meningococcal disease among contacts of smokers can-
not be reduced by simply banning smoking in confined
places like houses, work places, hospitals and vehicles,
but that a total ban is required.
But, all these studies are liable to bias as the informa-
tion about smoking status given by parents can at times
be misleading or ‘deceptive.’ More objective studies, for
example by the use of cotinine measurements, would
help to explore the association of meningococcal disease
with passive smoking. Also, whenever possible, future
studies should aim to tease out exposure to ‘passive
smoke’ from exposure to ‘smoker contact,’ so that the
role of smokers in increasing the risk of meningococcal
disease in household contacts can be understood more
clearly.
The study by Murray and colleagues highlights the
importance of stopping smoking for parents [3]. But in a
recently published large survey representing 3 billion
people from 16 countries, quitting ratios have been
found to be very low (< 20%) [11]. Other interventions
like health education, close monitoring of children for
meningococcal disease, tighter legislation (including plain
packaging) and targeted interventions for quitting smok-
ing in pregnancy could be employed. Vaccines may play
an important role by safeguarding household contacts of
smokers from contracting serious vaccine-preventable
diseases. But, ironically, despite a recognized association
between smoking and infection [2], smokers are not
generally considered as a risk group requiring vaccina-
tion. One exception is the recent recommendation of the
US Advisory Committee on Immunization Practices for
23-valent pneumococcal polysaccharide vaccine in smo-
kers aged 19 years or older [12]. But that recommenda-
tion is primarily focused on prevention of invasive
pneumococcal disease in smokers, not their household
contacts.
Immunizing children with a pneumococcal conjugate
vaccine has had enormous herd benefits for their par-
ents and grandparents [13]. Similarly for meningococcal
disease, vaccinating children against serogroup C and,
more recently, against serogroup A diseases has pro-
duced significant herd benefits to adults [14,15]. The
study by Murray and colleagues adds to a large body of
evidence suggesting that the risk of meningococcal dis-
ease in children increases on exposure to second-hand
smoking and/or smoker contacts. Therefore, vaccinating
children with conjugate meningococcal vaccines (as well
as the newly licensed meningococcal B vaccine) could
be an appropriate strategy to protect the children, and
hopefully also their adult smoker contacts (through herd
immunity). Nevertheless, further studies are needed to
evaluate the cost-effectiveness of such a strategy.
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